Embryo genetic testing did not improve IVF outcomes in young women with recurrent implantation failure

A BJOG analysis of a multicenter trial in China found that preimplantation genetic testing for aneuploidy did not raise live birth or pregnancy rates in women under 38 with recurrent implantation failure. The findings suggest non-genetic factors may play a bigger role than embryo chromosome screening in this group.

Why it matters: - Recurrent implantation failure is one of the hardest problems in IVF. - The study suggests embryo chromosome screening may not solve that problem for younger patients. - The findings could affect how fertility clinics decide when PGT-A is worth using.

What happened: - Researchers led by Dr. Yun Sun at Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, analyzed data from a large multicenter clinical trial. - The trial ran across eight fertility centers in China from 2018 to 2020. - The analysis looked at women under 38 with recurrent implantation failure after transfer of good-quality embryos. - The findings were published in BJOG: An International Journal of Obstetrics & Gynaecology. - The paper was titled Effect of Preimplantation Genetic Testing for Aneuploidy on Live Birth Rate in Young Women with Recurrent Implantation Failure: A Secondary Analysis of a Multicentre Randomised Trial.

The details: - The analysis included more than 485 women. - Forty-six women underwent PGT-A. - The embryos in the PGT-A group were created with intracytoplasmic sperm injection, or ICSI. - Researchers used next-generation sequencing to identify euploid embryos for transfer. - The comparison group received standard IVF or ICSI care without genetic testing. - Researchers matched the groups statistically before comparing outcomes after frozen-thawed blastocyst transfer. - PGT-A did not improve live birth rates. - PGT-A did not improve early pregnancy rates, confirmed pregnancy rates, implantation success or miscarriage rates. - The analysis also found no improvement in maternal or infant health outcomes. - The journal entry became available online on Dec. 16, 2024, and appeared in Volume 132, Issue S2 on April 15, 2025. - The DOI is 10.1111/1471-0528.18027.

Between the lines: - The results point away from embryo aneuploidy as the main explanation for implantation failure in younger women. - Endometrial conditions and embryo-uterus interactions may matter more in this group. - The study supports a growing view that IVF failure is not always fixed by more embryo testing. - The analysis has limits, including the small number of women who received PGT-A and the non-randomized use of genetic testing in the original trial. - Dr. Sun said routine use of PGT-A in younger women with recurrent implantation failure should be carefully evaluated.

What's next: - The authors say more research is needed to pinpoint why implantation fails and to build more personalized fertility treatments. - Future studies may help identify which patients, if any, benefit most from embryo genetic testing. - Clinics may use these results to reassess PGT-A in younger IVF patients with repeated failures.

The bottom line: - In young women with recurrent implantation failure, PGT-A did not improve IVF outcomes in this trial analysis, suggesting the main barrier may lie beyond embryo genetics.